Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Miller et al. found a reduction in liver metastases due to enhanced delivery of nano‐encapsulated platinum in the TME via TAMs in a breast cancer mouse model [87].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
The Chemistry of Fluorescent Bodipy Dyes: Versatility Unsurpassed
Ulrich, G., Ziessel, R., & Harriman, A. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200702070 · Cited by 3,161
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationMacrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationKamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Self-citationDelivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“While MPS uptake of nanomedicine formulations is considered to be a drawback for the therapy of most tumors, it might be beneficial for the treatment certain specific tumors, such as hepatocellular carcinoma, in which TAM may act as local drug reservoirs [58].”
BackgroundInfluentialRodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Self-citationConcepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
“It has been demonstrated that the mechanism by which nanoparticles enter solid tumors is more complex than previously thought (potentially going beyond simple extravasation through gaps in the endothelial lining) [7], and that immune cells in the tumor microenvironment play important roles in nanomedicines’ accumulati…”
BackgroundProgress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
“For examples, peritoneal macrophages may be harvested, incubated with drugs, typically in nanoparticle/liposome formulations, for loading, and then infused back to animals/patients [214][215], or nanoparticles with appropriate size and/or ligand may be directly injected in vivo and get uptaken by resident macrophages/…”
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Self-citationTransport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Self-citationQuantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
A framework for designing delivery systems
Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. W. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0759-5 · Cited by 524
Ren, Z., Sun, S., Sun, R., Cui, G., Hong, L., Rao, B., Li, A., Yu, Z., Kan, Q., & Mao, Z. (2020) · Advanced Materials · doi:10.1002/adma.201906024 · Cited by 446
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Tailoring Materials for Modulation of Macrophage Fate
Li, J., Jiang, X., Li, H., Gelinsky, M., & Gu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202004172 · Cited by 403
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Dane, E. L., Belessiotis-Richards, A., Backlund, C., Wang, J., Hidaka, K., Milling, L. E., Bhagchandani, S., Melo, M. B., Wu, S., Li, N., et al. (2022) · Nature Materials · doi:10.1038/s41563-022-01251-z · Cited by 333
Nanoparticles and innate immunity: new perspectives on host defence
Boraschi, D., Italiani, P., Palomba, R., Decuzzi, P., Duschl, A., Fadeel, B., & Moghimi, S. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.013 · Cited by 310
Evolution of macromolecular complexity in drug delivery systems
Kakkar, A., Traverso, G., Farokhzad, O. C., Weissleder, R., & Langer, R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0063 · Cited by 320
Self-citationTumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
“Researchers showed that the uptake of nanoparticles by tumor macrophages was an important mechanism for accumulation of the drug to be delivered into the tumor in a therapeutically beneficial manner and depletion of macrophages resulted in significant decreases of tumor nanoparticle deposition and makes the treatment…”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“found a reduction in liver metastases due to enhanced delivery of nano-encapsulated platinum in the TME via TAMs in a breast cancer mouse model [87].”
BackgroundDelivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
“It has recently become appreciated that nanocarrier accumulation in tumors is often mediated by uptake of particles in phagocytic myeloid cells [197,238,239].”
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Nano-palladium is a cellular catalyst for in vivo chemistry
Miller, M. A., Askevold, B., Mikula, H., Kohler, R. H., Pirovich, D., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms15906 · Cited by 288
Self-citationTailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Fujiwara, T., Yakoub, M. A., Chandler, A., Christ, A. B., Yang, G., Ouerfelli, O., Rajasekhar, V. K., Yoshida, A., Kondo, H., Hata, T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0591 · Cited by 269
The mechanisms of nanoparticle delivery to solid tumours
Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00154-9 · Cited by 257
“TAMs may also act as drug depots, potentially releasing nanoparticles over time 106 .”
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Hartshorn, C. M., Bradbury, M. S., Lanza, G. M., Nel, A. E., Rao, J., Wang, A. Z., Wiesner, U. B., Yang, L., & Grodzinski, P. (2018) · ACS Nano · doi:10.1021/acsnano.7b05108 · Cited by 258
Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location
Perry, J. L., Reuter, K. G., Luft, J. C., Pecot, C. V., Zamboni, W., & DeSimone, J. M. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00021 · Cited by 255
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
He, J., Li, C., Ding, L., Huang, Y., Yin, X., Zhang, J., Zhang, J., Yao, C., Liang, M., Pirraco, R. P., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902409 · Cited by 246
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Miller, M. A., Chandra, R., Cuccarese, M. F., Pfirschke, C., Engblom, C., Stapleton, S., Adhikary, U., Kohler, R. H., Mohan, J. F., Pittet, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal0225 · Cited by 225
“Given previous evidence that TNP delivery to tumors occurs indirectly through TAM (11), we hypothesized that RT could maximally improve TNP accumulation under conditions eliciting TAM increase.”
BackgroundMethodResultInfluentialSelf-citationNanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
“Unfortunately, the early promise of several therapeutic NPs has failed to translate clinically (2).”
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
Salvioni, L., Rizzuto, M. A., Bertolini, J. A., Pandolfi, L., Colombo, M., & Prosperi, D. (2019) · Cancers · doi:10.3390/cancers11121855 · Cited by 201
“In particular, tumor-associated macrophages (TAMs) are one of the primary biological barriers in cancer tissue invariably encountered by NCs, so that scientists tried to exploit this “disadvantage” using TAMs as a reservoir of nanovehicles, to increase the site-specific drug release [13,77].”
BackgroundLing, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209
Self-citationRadiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy
Erel-Akbaba, G., Carvalho, L. A., Tian, T., Zinter, M., Akbaba, H., Obeid, P. J., Chiocca, E. A., Weissleder, R., Kantarci, A. G., & Tannous, B. A. (2019) · ACS Nano · doi:10.1021/acsnano.8b08177 · Cited by 202
Self-citationRamanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
“Nanoliposomal carriers may thus exhibit comparably faster drug release rates than therapeutic nanoparticles with a more erosive, slower release mechanism (27, 43), which could possibly explain the lack of correlation between lesion response to nal-IRI and late binding events of FMX in this study.”
BackgroundProgress on Modulating Tumor‐Associated Macrophages with Biomaterials
Sylvestre, M., Crane, C. A., & Pun, S. H. (2020) · Advanced Materials · doi:10.1002/adma.201902007 · Cited by 180
Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment
Reichel, D., Tripathi, M., & Perez, J. M. (2019) · Nanotheranostics · doi:10.7150/ntno.30052 · Cited by 173
“demonstrated that the accumulation of platinum prodrug-loaded polymeric nanoparticles within tumor-associated macrophages alters the spatial distribution of drug within tumors and controls nanoparticle treatment efficacy, while the depletion of macrophages from tumors reduces nanoparticle treatment efficacy [42].”
BackgroundDosta, P., Cryer, A. M., Dion, M. Z., Shiraishi, T., Langston, S. P., Lok, D., Wang, J., Harrison, S., Hatten, T., Ganno, M. L., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01447-7 · Cited by 161
“…the PK of CDN-NPs, B16-F10 melanoma tumour-bearing mice were injected i.v., and the concentration of CDN and polymer was have explored the role of phagocytic immune cells in modulating NP penetration 22 , cellular distribution 22,23 and residence time 23,24 in the TME following extravasation.”
BackgroundTobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy
Czapar, A. E., Zheng, Y.-R., Riddell, I. A., Shukla, S., Awuah, S. G., Lippard, S. J., & Steinmetz, N. F. (2016) · ACS Nano · doi:10.1021/acsnano.5b07360 · Cited by 171
Self-citationTargeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 164
Cuccarese, M. F., Dubach, J. M., Pfirschke, C., Engblom, C., Garris, C., Miller, M. A., Pittet, M. J., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms14293 · Cited by 168
Self-citationZhang, Z., Wang, H., Tan, T., Li, J., Wang, Z., & Li, Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801840 · Cited by 165
Iron Oxide Nanoparticles-Based Vaccine Delivery for Cancer Treatment
Zhao, Y., Zhao, X., Cheng, Y., Guo, X., & Yuan, W. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01103 · Cited by 165
Artificial local magnetic field inhomogeneity enhances T2 relaxivity
Zhou, Z., Tian, R., Wang, Z., Yang, Z., Liu, Y., Liu, G., Wang, R., Gao, J., Song, J., Nie, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15468 · Cited by 161
Lim, S., Park, J., Shim, M. K., Um, W., Yoon, H. Y., Ryu, J. H., Lim, D., & Kim, K. (2019) · Theranostics · doi:10.7150/thno.38425 · Cited by 169
“In addition to killing cancer cells, NP-based drug delivery systems for ICD-inducing cytotoxic drug can modulate immune reaction in TMEs, resulting in anti-tumor immune response [45].”
BackgroundHe, H., Guo, C., Wang, J., Korzun, W. J., Wang, X.-Y., Ghosh, S., & Yang, H. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01892 · Cited by 158
Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery
Stapleton, S., Jaffray, D. A., & Milosevic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.021 · Cited by 168
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
“These cells can act as drug depots when CT compounds are delivered in nanoparticles, thereby ensuring local and prolonged delivery of the therapy (106).”
BackgroundA chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J., Nizzero, S., Liu, H., Li, F., Zhang, G., Li, Z., Shen, H., Blanco, E., & Ferrari, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14221-2 · Cited by 145
Zhou, X. W., Zhang, X., Han, S., Dou, Y., Liu, M., Zhang, L., Guo, J., Shi, Q., Gong, G., Wang, R., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04523 · Cited by 152
Kim, H.-Y., Li, R., Ng, T. S. C., Courties, G., Rodell, C. B., Prytyskach, M., Köhler, R. H., Pittet, M. J., Nahrendorf, M., Weissleder, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04338 · Cited by 151
Self-citationBeyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors
Belyaev, I. B., Griaznova, O. Y., Yaremenko, A. V., Deyev, S. M., & Zelepukin, I. V. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115550 · Cited by 161
“Miller et al. conducted high-resolution microscopic imaging in tumor-bearing mice with dorsal window chamber to show that TAMs can act as long-term drug reservoirs in tumors [80].”
InfluentialLeveraging Engineering of Cells for Drug Delivery
Chen, Z., Hu, Q., & Gu, Z. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00526 · Cited by 148
Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments
Sun, T., & Jiang, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114773 · Cited by 137
Nanomaterial-based contrast agents
Hsu, J. C., Tang, Z., Eremina, O. E., Sofias, A. M., Lammers, T., Lovell, J. F., Zavaleta, C. L., Cai, W., & Cormode, D. P. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00211-4 · Cited by 159
Integrating Nanotechnology into Cancer Care
Grodzinski, P. A., Kircher, M. F., Goldberg, M. S., & Gabizón, A. (2019) · ACS Nano · doi:10.1021/acsnano.9b04266 · Cited by 147
Yu, G., Zhu, B., Shao, L., Zhou, J., Saha, M. L., Shi, B., Zhang, Z., Hong, T., Li, S., Chen, X. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902029116 · Cited by 136
Particle Targeting in Complex Biological Media
Dai, Q., Bertleff‐Zieschang, N., Braunger, J. A., Björnmalm, M., Cortez‐Jugo, C., & Caruso, F. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700575 · Cited by 139
Tan, T., Hu, H., Wang, H., Li, J., Wang, Z., Wang, J., Wang, S., Zhang, Z., & Li, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-11235-4 · Cited by 132
Li, R., Ng, T. S. C., Wang, S. J., Prytyskach, M., Rodell, C. B., Mikula, H., Köhler, R. H., Garlin, M. A., Lauffenburger, D. A., Parangi, S., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00897-1 · Cited by 138
Self-citationMills, J. A., Liu, F., Jarrett, T. R., Fletcher, N. L., & Thurecht, K. J. (2022) · Biomaterials Science · doi:10.1039/d2bm00181k · Cited by 138
Photoactivated Lysosomal Escape of a Monofunctional Pt II Complex Pt‐BDPA for Nucleus Access
Xue, X., Qian, C., Fang, H., Liu, H., Yuan, H., Guo, Z., Bai, Y., & He, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201906203 · Cited by 128
Clinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 130
Lee, S. H., Park, O. K., Kim, J., Shin, K., Pack, C., Kim, K., Ko, G., Lee, N., Kwon, S., & Hyeon, T. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04621 · Cited by 127
Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking
Sofias, A. M., Toner, Y. C., Meerwaldt, A. E., van Leent, M. M. T., Soultanidis, G. M., Elschot, M., Gonai, H., Grendstad, K., Flobak, Å., Neckmann, U., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b08693 · Cited by 128
Ultrasound and microbubbles to beat barriers in tumors: Improving delivery of nanomedicine
Snipstad, S., Vikedal, K., Maardalen, M., Kurbatskaya, A., Sulheim, E., & Davies, C. D. L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113847 · Cited by 127
Neutrophils and Macrophages as Targets for Development of Nanotherapeutics in Inflammatory Diseases
Su, Y., Gao, J., Kaur, P., & Wang, Z. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121222 · Cited by 128
Principles of Nanoparticle Delivery to Solid Tumors
Chan, W. C. W. (2023) · BME Frontiers · doi:10.34133/bmef.0016 · Cited by 126
“Miller et al. [49,50] and Dai et al. [51] showed that the TAMs take up many nano-particles after crossing the tumor blood vessel.”
BackgroundMacrophages Actively Transport Nanoparticles in Tumors After Extravasation
Lin, Z. P., Nguyen, L. N. M., Ouyang, B., MacMillan, P., Ngai, J., Kingston, B. R., Mladjenovic, S. M., & Chan, W. C. W. (2022) · ACS Nano · doi:10.1021/acsnano.1c11578 · Cited by 128
Targeted Theranostic Nanoparticles for Brain Tumor Treatment
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040181 · Cited by 119
Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions
Anchordoquy, T. J., Artzi, N., Balyasnikova, I. V., Barenholz, Y., La-Beck, N. M., Brenner, J. S., Chan, W. C. W., Decuzzi, P., Exner, A. A., Gabizón, A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00182 · Cited by 130
Safety of nanosuspensions in drug delivery
Wang, L., Du, J., Zhou, Y., & Wang, Y. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.007 · Cited by 115
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 124
“In this respect a fact must be mentioned that nanoscale agents can also be accumulated by tumor associated macrophages which act in this case as a reservoir, gradually releasing the active substance, which significantly prolongs the presence of the agent in the tumor [113].”
BackgroundMagnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics
Efremova, M. V., Naumenko, V., Spasova, M., Garanina, A. S., Abakumov, M. A., Blokhina, A. D., Melnikov, P., Prelovskaya, A. O., Heidelmann, M., Li, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29618-w · Cited by 116
Qiu, N., Wang, G., Wang, J., Zhou, Q., Guo, M., Wang, Y., Hu, X., Zhou, H., Bai, R., You, M., et al. (2020) · Advanced Materials · doi:10.1002/adma.202006189 · Cited by 116
Nanomedicine Strategies to Target Tumor-Associated Macrophages
Binnemars-Postma, K., Storm, G., & Prakash, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050979 · Cited by 108
“Macrophages may also act as a drug depot, which accumulates drug-loaded nanoparticles and releases them over time [114].”
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy
Si, J., Shao, S., Shen, Y., & Wang, K. (2016) · Small · doi:10.1002/smll.201601282 · Cited by 109
Nanoparticles for Cancer Diagnosis, Radionuclide Therapy and Theranostics
Llop, J., & Lammers, T. (2021) · ACS Nano · doi:10.1021/acsnano.1c09139 · Cited by 111
Xiong, F., Ling, X., Chen, X., Chen, J., Tan, J., Cao, W., Ge, L., Ma, M., & Wu, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00824 · Cited by 103
Lu, K.-Y., Lin, P.-Y., Chuang, E.-Y., Shih, C.-M., Cheng, T.-M., Lin, T.-Y., Sung, H.-W., & Mi, F.-L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15515 · Cited by 102
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning
Kingston, B. R., Syed, A. M., Ngai, J., Sindhwani, S., & Chan, W. C. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907646116 · Cited by 107
“Future iterations of our predictive algorithm could evaluate the addition of new parameters such as extracellular matrix composition and presence of stromal cells, which have shown to be important for nanoparticle delivery to primary tumors (5, 6, 18, 33).”
MethodMiller, M. A., Mikula, H., Luthria, G., Li, R., Kronister, S., Prytyskach, M., Kohler, R. H., Mitchison, T., & Weissleder, R. (2018) · ACS Nano · doi:10.1021/acsnano.8b07954 · Cited by 97
Self-citationRecent advances in targeted nanomedicine as promising antitumor therapeutics
Hejmady, S., Pradhan, R., Alexander, A., Agrawal, M., Singhvi, G., Gorain, B., Tiwari, S., Kesharwani, P., & Dubey, S. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.031 · Cited by 99
Peng, C., Huang, Y., & Zheng, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.020 · Cited by 102
“, tumorassociated macrophages, TAMs), also limit DDS penetration and targeting to cancer cells [98,99].”
Background
Metadata
- Authors
- Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., Kolishetti, N., Pittet, M., Lippard, S. J., Farokhzad, O. C., & Weissleder, R.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Weissleder, Ralph
- ORCID
- Venue
- Nature Communications
- Published
- 2015-10-27
- Volume
- 6
- Issue
- 1
- Pages
- 8692-8692
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4711745
- OpenAlex
- W1874889006
- Cited by
- 441
- References
- 70
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 38 · 2023: 40 · 2022: 40 · 2021: 46 · 2020: 62 · 2019: 55 · 2018: 48 · 2017: 42 · 2016: 23
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Deutsche Forschungsgemeinschaft (PF809/1-1, CA034992)
- National Institutes of Health (CA151884, U54-CA151884, CA034992, CA139980, PO1-CA139980)
- National Cancer Institute (CA-034992, CA139980, P50CA086355, R01CA164448, U54CA151884, P01CA139980, R37CA034992, CA151884, R01CA034992, P30CA014051, T32CA079443)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- tumour-associated macrophages, nanotherapeutics, pharmacodynamics, single-cell imaging, DNA damage response, slow drug release, TAM depletion, nanoparticle accumulation, cancer nanomedicine
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Macrophages, Mice, Inbred C57BL, Mice, Nude, Neoplasms, Platinum, Prodrugs, Drug Delivery Systems, Cell Line, Tumor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.